# reload+after+2024-01-20 05:45:41.416547
address1§9920 Pacific Heights Blvd
address2§Suite 150
city§San Diego
state§CA
zip§92121
country§United States
phone§858 350 4364
website§https://www.kintara.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
fullTimeEmployees§2
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Robert E. Hoffman B.B.A., CPA', 'age': 57, 'title': 'President, CEO, Interim CFO & Chairman of the Board', 'yearBorn': 1966, 'fiscalYear': 2023, 'totalPay': 767980, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeffrey A. Bacha B.Sc., M.B.A.', 'age': 55, 'title': 'Founder', 'yearBorn': 1968, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Greg A. Johnson', 'title': 'Acting Head of Operations', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.667
currency§USD
dateShortInterest§1702598400
forwardEps§-0.83
exchange§NCM
quoteType§EQUITY
shortName§Kintara Therapeutics, Inc.
longName§Kintara Therapeutics, Inc.
firstTradeDateEpochUtc§1361543400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e1a651ad-fadc-3afa-99fa-0bb9278fafcd
gmtOffSetMilliseconds§-18000000
targetHighPrice§14.0
targetLowPrice§14.0
targetMeanPrice§14.0
targetMedianPrice§14.0
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§0.065
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
